Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Cancrinase 3750IU Injection
Manufacturer/Marketed By : MANKIND PHARMACEUTICALS LIMITED
$242.69 $194.16
Cancrinase 3750IU Injection is a chemotherapy drug containing the active constituent Pegaspargase. It is used to treat a type of blood cancer called Acute Lymphoblastic Leukemia (ALL). This is a...
PEGASPARGASE
Active Pharmaceutical Ingredient
Cancrinase 3750IU Injection
$242.69
$194.16
Cancrinase 3750IU Injection is a chemotherapy drug containing the active constituent Pegaspargase. It is used to treat a type of blood cancer called Acute Lymphoblastic Leukemia (ALL). This is a white blood cell cancer in which the immature white cells start growing out of control, thus preventing the production of functional blood cells. Combined with other chemotherapy drugs, this medication can help increase the chances of remission and long-term survival for people with ALL. It is particularly effective in treating children with ALL, who have a higher remission rate and overall survival when included in their treatment plan. Cancrinase 3750IU Injection is typically used with other chemotherapy agents to treat ALL, particularly in patients who have not responded to other treatments or who have relapsed after initial treatment. Glucose intolerance can occur with the administration of Cancrinase 3750IU Injection. Contact your doctor if you experience severe headaches, abdominal pain, excessive thirst, or serious allergic reactions while taking this medicine. Patients with previous kidney and pancreatic disease should talk to their healthcare provider before taking this medication.
Active Pharmaceutical Ingredient
Uses
• Acute Lymphoblastic Leukemia
• Non-Hodgkin's Lymphoma
Benefits
Cancrinase 3750IU Injection is an enzyme that breaks down the amino acid asparagine in the body. Cancer cells require asparagine to grow and divide and cannot produce their asparagine. By breaking down asparagine in the body, this medication can effectively "starve" cancer cells of this essential nutrient, slowing their growth and promoting cancer cell death. However, normal cells in the body can produce their asparagine and are not as affected by the enzyme as cancer cells. Therefore, this medicine selectively targets cancer cells while sparing healthy cells in the body to some extent.
Side Effects
Like all medications, Cancrinase 3750IU Injection can cause side effects, although not everyone who takes it will experience them.
Most Common Side Effects
• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Loss of appetite
• Headache
• Fever or chills
• Muscle or joint pain
• Rash or itching
• Swelling or redness at the injection site
Common Side Effects
• Anaphylaxis (severe allergic reaction)
• Thrombosis (blood clots)
• Hemorrhage (bleeding)
• Tumor Lysis Syndrome (a potentially life-threatening condition due to the breakdown of cancer cells)
• Acute pancreatitis (inflammation of the pancreas)
• Hepatotoxicity (liver damage or failure)
• Neurotoxicity (damage to the nervous system)
• Hypersensitivity reactions (allergic reactions, including anaphylaxis)
• Renal failure (kidney damage or failure)
How To Use
Cancrinase 3750IU Injection is typically administered by a healthcare provider as an intravenous (IV) injection in a clinical setting. The dosage and frequency of infusions will vary depending on the patient's medical condition, age, weight, and other factors. You should not take a double dose to make up the second dose.
Safety Advice
• Breast Feeding: It is unclear whether Cancrinase 3750IU Injection is excreted in human milk. So you should consult a doctor before taking this medication if you are a breastfeeding mother.
• Alcohol: It is recommended to avoid consuming alcohol while taking Cancrinase 3750IU Injection, as alcohol can increase the risk of certain side effects associated with the medication, such as stomach ulcers or gastrointestinal bleeding.
• Liver: Cancrinase 3750IU Injection is primarily metabolized in the liver, so inform your healthcare provider if you have any liver problems or diseases. This medication may also increase liver enzymes, which can be a sign of liver damage or inflammation. Patients taking this medication require regular blood tests to monitor liver function.
• Lungs: There is no evidence to suggest that Cancrinase 3750IU Injection harms the lungs. However, as with any medication, there is a risk of side effects that could affect the respiratory system. So patients should consult their doctor if they have any pre-existing lung disease before taking this medication.
• Driving: Patients receiving Cancrinase 3750IU Injection should be advised to avoid driving or operating machinery if they experience side effects such as fatigue, dizziness, or blurred vision, impairing a patient's ability to drive or operate machinery safely.
• Pregnancy: There are no established adverse effects of Cancrinase 3750IU Injection in pregnant women. Consult your doctor if you are pregnant or planning to get pregnant before taking this medicine.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.